Prostate cancer spit test is better for men with high genetic risk than the standard PSA blood test – ICR
The Institute of Cancer Research (ICR) shared a post on LinkedIn:
“Breaking News: Prostate cancer spit test is better for men with high genetic risk than the standard PSA blood test.
The saliva test detects genetic variants linked to prostate cancer.
For men with high genetic risk, the test gave fewer false positives and picked up a higher proportion of aggressive cancers than the PSA test, meaning fewer men could be sent for unnecessary testing.
Dheeresh (pictured on the right) was diagnosed with prostate cancer through the BARCODE1 trial. He said:
‘Because the saliva test revealed that I had a high genetic risk my younger brother signed up and discovered that he also had an aggressive tumour. It’s incredible to think that because of this study two lives have now been saved in my family.’
The results from the ICR’s BARCODE 1 trial are published in the New England Journal of Medicine (NEJM Group).
Read more here.”
More posts featuring ICR.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023